...
首页> 外文期刊>Neurogastroenterology and motility >The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis
【24h】

The American neurogastroenterology and motility society gastroparesis cardinal symptom index‐daily diary (ANMS GCSI‐DD): Psychometric evaluation in patients with idiopathic or diabetic gastroparesis

机译:美国神经科学生学和运动社会胃泌尿病基本症状指数指数日记(ANMS GCSI-DD):特发性或糖尿病胃病患者的心理测量评估

获取原文
获取原文并翻译 | 示例

摘要

Abstract Background The purpose of this study was to evaluate the measurement properties of the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index‐Daily Diary, a patient‐reported outcome instrument developed to meet US FDA recommendations for a symptom‐based clinical trial endpoint in gastroparesis. The ANMS GCSI‐DD assesses nausea, early satiety, postprandial fullness, and upper abdominal pain on a severity score from none (0) to very severe (4) and number of vomiting episodes during the past 24 hours. The composite score includes the first four symptoms, the core symptom score includes all five symptoms. Methods Seventy‐one patients diagnosed with idiopathic or diabetic gastroparesis were recruited for a four‐week observational study. Patients completed the ANMS GCSI‐DD at home between Baseline and Week 4. Statistical analyses included confirmatory factor analysis, item response theory analysis, internal consistency, test‐retest reliability, and construct and known‐groups validity. Key Results Unidimensionality for the composite and core symptom scores was supported, and items exhibited good fit. Internal consistency (Cronbach's alpha =0.85 and 0.83) and test‐retest reliability were 0.89 and 0.88, for composite and core symptom scores, respectively. Convergent validity was supported by strong correlations with patient‐reported and clinician measures. Baseline and Week 4 scores differed for three measures used to define disease severity status ( P ??0.0001), supporting known‐groups validity. Conclusions & Inferences The ANMS GCSI‐DD has excellent reliability and validity, supporting its use to assess symptom‐based endpoints in gastroparesis clinical studies. Further analyses will be conducted using clinical trial data to ascertain treatment responsiveness and define a responder.
机译:摘要背景本研究的目的是评估美国神经科学生学和运动社会胃塔内酯基本症状指数日记的测量性质,这是一个患者报告的结果仪表,以满足美国FDA对胃流血症状的临床试验终点的建议。 ANMS GCSI-DD评估恶心,早期饱腹感,后腹部,和上腹部疼痛,从无(0)到非常严重(4)和过去24小时内的呕吐发作的数量。综合评分包括前四种症状,核心症状评分包括所有五种症状。方法促进七十一名患者,招募了为期四周的观察性研究。患者在基线和第4周之间完成了Home的ANMS GCSI-DD。统计分析包括确认因子分析,项目响应理论分析,内部一致性,测试 - 保持可靠性和构建和已知组有效性。关键结果支持综合和核心症状分数的单向性,物品表现出良好。内部一致性(Cronbach的alpha = 0.85和0.83)和测试 - 重保持可靠性分别为0.89和0.88,分别用于复合和核心症状分数。通过与患者报告和临床医生措施的强烈相关性支持收敛有效性。基线和第4周的分数对于用于定义疾病严重程度状态的三项措施(p≤0.0001),支持已知组有效性。结论&推论ANMS GCSI-DD具有优异的可靠性和有效性,支持其用于评估胃流离失核心临床研究中基于症状的终点。将使用临床试验数据进行进一步分析,以确定治疗响应性并定义响应者。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号